VIENNA—At the St Gallen Breast Cancer Conference BCL-2 was named as a therapeutic target for patients with hormone-receptor positive breast cancer by Geoffrey J Lindeman BSc(Med) PhD, from the University of Melbourne and the Walter and Eliza Hall Institute of Medical Research and head of the Familial Cancer Centre at The Royal Melbourne Hospital, Australia. He discussed the clinical potential of BCL-2 modulation with Oncology Times reporter Sarah Maxwell.
You may also like...
World Malaria Day 2012: Dr Chi Eziefula, LSHTM: Old Drug New Hopes 24 Apr, 2012 PD-L1 Checkpoint Inhibitor Immunotherapy Boosts Survival in Lung Cancer 6 Dec, 2016 Patients with oropharyngeal cancer: no HPV risk to spouses, partners 21 Jun, 2013 Multi-Gene Assays Now Recommended To Refine Chemotherapy Decisions in Breast Cancer 15 Apr, 2009
- Previous story Tumor Microenvironment: Tumor Infiltrating Lymphocyte Score Predicts Breast Cancer Outcome
- Next story Targeting Bone Microenvironment in Breast Cancer
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014